Compare Biogen Inc (BIIB) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Corning Incorporated — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Corning Incorporated trades at $173.23 (market cap $161.49B). The key difference: Corning Incorporated is far larger — about 5.7× Biogen Inc's market cap, and Corning Incorporated pays a 0.6% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GLW | |
|---|---|---|
Market Cap | $28.34B | $161.49B |
Sector | Health | Technology |
52-Week High | $216.63 | $255.79 |
52-Week Low | $122.68 | $52.97 |
Enterprise Value | $30.62B | $169.66B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Corning (GLW) trades at $183.36, down 3.92% amid a broader AI infrastructure stock selloff. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.70 versus $0.692 expected, marking the fourth consecutive earnings beat. Revenue growth accelerated to $15.63 billion in 2025 with net income margin improving to 10.21%. Technical indicators show bearish momentum with the price testing support at $181, while RSI at 46.51 suggests neutral momentum conditions.
GLW presents a compelling long-term opportunity with 54% analyst buy ratings and a $210.10 consensus price target representing 15% upside. Key risks include China exposure, consumer electronics cyclicality, and competitive pressures in optical communications. The company's AI partnerships with NVIDIA and Amazon position it well for sustained growth in fiber and connectivity markets despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
